Regeneron reports Pasatru results for Regeneron stock

Published on 10/20/2026 at 10:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Pasatru showed zero new lesions versus 9 for placebo at week 84 on October 12, 2026. Regeneron stock trades at EUR 698.45 on October 20, 2026.

Pasatru data and upcoming results

Regeneron's October 12, 2026 Pasatru update reported zero new lesions versus 9 for placebo at week 84.
Second-quarter 2026 revenue reached USD 4.29 billion, up 16.7 percent year over year.
Regeneron stock was trading at EUR 698.45 at 10:47 a.m. CEST at Lang & Schwarz on October 20, 2026.

Geometrisches Bauhaus-Poster mit Molekülformen und dem Wort PHARMA in Primärfarben — Regeneron Pharma US75886F1075 verwendet ein Bauhaus-Poster mit geometrischen Formen, Molekülmotiven und großem Schriftzug PHARMA, Illustration mit AI erstellt.

Regeneron (ISIN US75886F1075) was trading at EUR 698.45 at Lang & Schwarz on October 20, 2026 at 10:47 a.m. CEST. On October 12, 2026, Regeneron reported 84-week Pasatru results showing zero new heterotopic ossification lesions versus 9 for placebo.

Pasatru delivers a quantified signal

The OPTIMA extension enrolled 63 adults, with 58 participants completing the double-blind extension phase to at least 84 weeks. The treatment groups also recorded 1 and 14 clinician-assessed flare-ups, compared with 17 for placebo, while skin and soft tissue infections occurred in 53 percent of the 3 mg/kg group and 78 percent of the 10 mg/kg group.

What does the pipeline update mean?

The result adds a late-stage rare-disease data point to Regeneron's broader development platform. The company said a Phase 3 trial in adolescents and children is planned to begin later in 2026, keeping execution and safety data central to the commercial outlook.

Three dated developments

On July 30, 2026, Regeneron reported second-quarter revenue of USD 4.29 billion, up 16.7 percent year over year, while adjusted earnings per share reached USD 14.29 versus USD 10.16 expected, according to MarketBeat. On October 1, 2026, GlobeNewswire reported an expanded Sanofi alliance with USD 1.00 billion upfront and up to USD 7.00 billion in milestone payments. On October 12, 2026, Regeneron published the Pasatru update.

Upcoming results set the next date

Regeneron scheduled its third-quarter 2026 financial and operating results for October 30, 2026, before U.S. markets open, followed by an 8:30 a.m. ET conference call. That release gives investors a fixed date for testing whether the second-quarter revenue growth continued.

Stock trades in after-hours context

Regeneron's market capitalization stood at USD 80.5 billion on October 19, 2026, while its Nasdaq 52-week range was USD 572.75 to USD 859.34, according to the market data summarized by MarketBeat. The company is listed on Nasdaq under the ticker REGN, and its next scheduled report is October 30, 2026. Regeneron was trading at EUR 698.45 at Lang & Schwarz on October 20, 2026 at 10:47 a.m. CEST.

The further course of trading is shown by the continuously updated real-time quote of Regeneron stock.